European Journal of Clinical Investigation · 1986 · 14 citations · 14 references
MedicineHematologyPharmacologyHemostasisPharmacokinetic VariabilityVascular SurgeryAnticoagulant TherapyAnticoagulation TherapyDeep Vein ThrombosisHemostatic AgentsThrombosisThrombotic DisordersAnticoagulation RegimenCoagulationHeparin AnticoagulationHeparin-mediated AnticoagulationInterindividual VariationIntravenous Bolus InjectionMonitoring Of Anticoagulant TherapySubjects
In some patients affected with deep vein thrombosis (DVT) it is necessary to administer large doses of heparin to achieve proper anticoagulation. To investigate the clinical relevance of this phenomenon, we studied the heparin half-life and the heparin sensitivity after a bolus IV injection of 60 i.u. kg-1 in seven healthy volunteers and eight DVT patients investigated on day 1 or 2 and again between day 10 and 20 of the heparin therapy. The heparin half-life, the in vitro and ex vivo heparin sensitivity, were comparable in the healthy volunteers and in the patients at both times of investigation. However, there were large interindividual variations in the controls and in the patients, not correlated to the levels of any coagulation factors. Thus, the heparin hyperconsumption phenomenon occasionally observed in a given patient reflected individual characteristics and was no value in the diagnosis of DVT.
14
Heparin kinetics in venous thrombosis and pulmonary embolism.
J. Hirsh, W.G. van Aken, Alexander Gallus et al. · Circulation · 1976 · 277 citations · Full text
Medicine, Hematology, Pharmacology +15
J. Hirsh, WL Yung, E. Regoeczi et al. · Blood · 1977 · 184 citations · Full text
Medicine, Hematology, Pharmacology +11